12 Month Price Forecast For INTS
Distance to INTS Price Forecasts
INTS Price Momentum
๐ค Considering Intensity Therapeutics (INTS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 3:40 AM UTC
INTS Analyst Ratings & Price Targets
Based on our analysis of 3 Wall Street analysts, INTS has a bullish consensus with a median price target of $10.00 (ranging from $4.00 to $16.00). Currently trading at $2.32, the median forecast implies a 331.0% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INTS Analyst Consensus
INTS Price Target Range
Latest INTS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INTS.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 13, 2025 | Alliance Global Partners | James Molloy | Buy | Initiates | $8.50 |
Nov 21, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $5.00 |
Oct 31, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Initiates | $5.00 |
Jul 11, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
May 16, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
Mar 21, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
Nov 14, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
Aug 24, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
Jul 18, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Initiates | $12.00 |
Stocks Similar to Intensity Therapeutics, Inc. - Common Stock
The following stocks are similar to Intensity Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Intensity Therapeutics, Inc. - Common Stock (INTS) Financial Data
Intensity Therapeutics, Inc. - Common Stock has a market capitalization of $34.19M with a P/E ratio of -1.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -147.2%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Intensity Therapeutics, Inc. - Common Stock (INTS) Company Overview
About Intensity Therapeutics, Inc. - Common Stock
Develops innovative cancer treatment therapies.
The company focuses on discovering and developing cancer drugs, primarily targeting refractory solid tumors. It generates revenue through the advancement of its lead product candidate, INT230-6, which is currently undergoing various phases of clinical trials.
Intensity Therapeutics, Inc. was founded in 2012 and is headquartered in Shelton, Connecticut, positioning itself within the clinical-stage biotechnology sector in the United States.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
5
CEO
Mr. Lewis H. Bender M.A., M.B.A., M.S.
Country
United States
IPO Year
2022
Website
www.intensitytherapeutics.comIntensity Therapeutics, Inc. - Common Stock (INTS) Latest News & Analysis
Intensity Therapeutics' Phase 3 INVINCIBLE-3 study for sarcoma therapies continues recruitment, with approvals in the U.S., Canada, Europe, and Australia. The study will proceed without changes.
The continuation of the INVINCIBLE-3 Study without modifications signals confidence in Intensity Therapeutics' cancer treatment, potentially boosting investor sentiment and stock performance.
Intensity Therapeutics has received regulatory approvals for its Phase 3 study on metastatic soft tissue sarcoma and is conducting a Phase 2 trial for triple-negative breast cancer in Switzerland.
Regulatory approvals for clinical studies enhance Intensity Therapeutics' credibility and potential for breakthroughs in cancer treatment, impacting stock performance and investor sentiment.
Intensity Therapeutics has activated seven clinical trial sites in Switzerland for its novel intratumoral cancer therapies. Enrollment is currently ongoing.
The activation of seven clinical trial sites in Switzerland signals progress for Intensity Therapeutics, potentially boosting its stock value and attracting investor interest in its cancer therapies.
Intensity Therapeutics has signed a securities purchase agreement to sell 1,237,113 shares of common stock at $2.425 per share to a healthcare-focused institutional investor.
Intensity Therapeutics' securities purchase agreement signals investor interest and funding for its cancer therapies, potentially impacting stock performance and future growth prospects.
Phase 1/2 data for INT230-6 showed a median overall survival of 21.3 months, compared to 6.7 months in synthetic controls. The INVINCIBLE-3 Study is recruiting 333 patients across several countries.
Positive survival data and strong safety profiles for INT230-6 could boost Intensity Therapeutics' stock value, attract investment interest, and enhance its market position in cancer therapies.
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
2 months agoIntensity Therapeutics has dosed the first patient in a Phase 2 study for presurgical triple negative breast cancer. The company also announced its Q3 2024 financial results.
The initiation of a Phase 2 study signals progress in Intensity's drug development, potentially boosting investor confidence and impacting stock performance in the biotechnology sector.
Frequently Asked Questions About INTS Stock
What is Intensity Therapeutics, Inc. - Common Stock's (INTS) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Intensity Therapeutics, Inc. - Common Stock (INTS) has a median price target of $10.00. The highest price target is $16.00 and the lowest is $4.00.
Is INTS stock a good investment in 2025?
According to current analyst ratings, INTS has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for INTS stock?
Wall Street analysts predict INTS stock could reach $10.00 in the next 12 months. This represents a 331.0% increase from the current price of $2.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Intensity Therapeutics, Inc. - Common Stock's business model?
The company focuses on discovering and developing cancer drugs, primarily targeting refractory solid tumors. It generates revenue through the advancement of its lead product candidate, INT230-6, which is currently undergoing various phases of clinical trials.
What is the highest forecasted price for INTS Intensity Therapeutics, Inc. - Common Stock?
The highest price target for INTS is $16.00 from at , which represents a 589.7% increase from the current price of $2.32.
What is the lowest forecasted price for INTS Intensity Therapeutics, Inc. - Common Stock?
The lowest price target for INTS is $4.00 from at , which represents a 72.4% increase from the current price of $2.32.
What is the overall INTS consensus from analysts for Intensity Therapeutics, Inc. - Common Stock?
The overall analyst consensus for INTS is bullish. Out of 3 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are INTS stock price projections?
Stock price projections, including those for Intensity Therapeutics, Inc. - Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.